secwatch.observer — SEC 8-K summary
======================================

Issuer:     Camp4 Therapeutics Corp (CAMP)
CIK:        0001736730
Form:       8-K
Filed at:   2025-08-14T23:59:59+00:00
Accession:  0001736730-25-000068
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CAMP4 reports Q2 net loss of $12.6M; cash $39.1M; pipeline advances in SYNGAP1 and UCD programs
--------------------------------------------------------------------------------

- Net loss of $12.6M for Q2 2025, flat vs Q2 2024; R&D expenses $10.3M, G&A $4.2M.
- Cash, cash equivalents and marketable securities $39.1M as of June 30, 2025, down from $49.3M on March 31, 2025.
- SYNGAP1 program: translational data presented at ASGCT; GLP tox studies start Q3 2025; potential Phase 1/2 trial in H2 2026.
- CMP-CPS-001 (UCD): completed dosing in MAD cohort 3; safety and biomarker data from SAD and MAD cohorts expected Q4 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1736730/000173673025000068/0001736730-25-000068-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1736730/000173673025000068/camp-20250814.htm
  HTML page:      https://secwatch.observer/filing/0001736730-25-000068

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer